Curaleaf International Medical Cannabis Inhaler Approved in Australia and New Zealand

Curaleaf International's Que Medical Inhalation Device (QMID) has achieved regulatory registration in Australia and has been made available in New Zealand. The device was listed on Australia's Register of Therapeutic Goods (ARTG) by the Therapeutic Goods Administration (TGA) on September 15, 2026, marking the first liquid Cannabis Sativa L. extract inhalation delivery device to receive regulatory approval in the country.

This registration allows Australian and New Zealand clinicians to prescribe a liquid cannabis inhalation device that has been formally approved, providing standardized dosing akin to other pharmaceuticals. Curaleaf stated this reflects the level of clinical evidence, safety testing, and regulatory scrutiny applied to new technologies before patient use.

QMID was also added to the Web Assisted Notification of Devices (WAND) database, operated by Medsafe, New Zealand's medicines and medical devices regulator, on September 17, 2026. These registrations signify a notable advancement in the Australasian medical cannabis market and for the regulatory pathways of cannabis-based medical devices.

The QMID device, designed to aerosolize medication, offers patients and prescribers a controlled delivery system for consistent dosing and comparable clinical data. It features a compact design for discreet use and reusable hardware compatible only with approved cartridges.